A prospective multi-institutional study has been initiated in Japan to evaluate the feasibility of induction chemotherapy using pemetrexed plus cisplatin, followed by pleurectomy/decortica-tion aimed at macroscopic complete resection in patients with resectable malignant pleural mesothelioma. The study was initiated on September 2012, for which 24 patients will be recruited over a period of 2 years. The primary endpoint is the macroscopic complete resec-tion rate, regardless of the surgical technique employed (i.e. pleurectomy/decortication or extrapleural pneumonectomy). The secondary endpoints are the pleurectomy/decortication rate, macroscopic complete resection rate by pleurectomy/decortication, pulmonary function at 3 months after surg...
BACKGROUND: The aim of this multicenter trial was to prospectively evaluate neo-adjuvant chemotherap...
HYPOTHESIS: The effectiveness of extrapleural pneumonectomy (EPP) to extend quality-adjusted surviva...
INTRODUCTION: Malignant pleural mesothelioma is an ideal model for testing new locoregional multimod...
A prospective multi-institutional study has been commenced in Japan to evaluate the feasibility of i...
BACKGROUND: Malignant pleural mesothelioma is an aggressive tumor that has a poor prognosis and is r...
Radical multimodality treatment for malignant pleural mesothelioma (MPM) is controversial, with inte...
INTRODUCTION:Mesothelioma remains a lethal cancer. To date, systemic therapy with pemetrexed and a p...
textabstractThe European Organisation for Research and Treatment of Cancer (EORTC; protocol 08031) p...
Introduction:We developed an innovative approach for malignant pleural mesothelioma (MPM) with a sho...
Malignant pleural mesothelioma (MPM) is an aggressive disease with poor prognosis and the current tr...
The European Organisation for Research and Treatment of Cancer (EORTC; protocol 08031) phase II tria...
Background: Pemetrexed in combination with cisplatin (Pem/Cis) is used globally for the treatment of...
BACKGROUND: Trimodality therapy seems to be the best treatment for malignant pleural mesothelioma (M...
INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive neoplasia. Multidisciplinary tre...
Objective: From therapeutic nihilism to extremely aggressive management, there is a wide range of po...
BACKGROUND: The aim of this multicenter trial was to prospectively evaluate neo-adjuvant chemotherap...
HYPOTHESIS: The effectiveness of extrapleural pneumonectomy (EPP) to extend quality-adjusted surviva...
INTRODUCTION: Malignant pleural mesothelioma is an ideal model for testing new locoregional multimod...
A prospective multi-institutional study has been commenced in Japan to evaluate the feasibility of i...
BACKGROUND: Malignant pleural mesothelioma is an aggressive tumor that has a poor prognosis and is r...
Radical multimodality treatment for malignant pleural mesothelioma (MPM) is controversial, with inte...
INTRODUCTION:Mesothelioma remains a lethal cancer. To date, systemic therapy with pemetrexed and a p...
textabstractThe European Organisation for Research and Treatment of Cancer (EORTC; protocol 08031) p...
Introduction:We developed an innovative approach for malignant pleural mesothelioma (MPM) with a sho...
Malignant pleural mesothelioma (MPM) is an aggressive disease with poor prognosis and the current tr...
The European Organisation for Research and Treatment of Cancer (EORTC; protocol 08031) phase II tria...
Background: Pemetrexed in combination with cisplatin (Pem/Cis) is used globally for the treatment of...
BACKGROUND: Trimodality therapy seems to be the best treatment for malignant pleural mesothelioma (M...
INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive neoplasia. Multidisciplinary tre...
Objective: From therapeutic nihilism to extremely aggressive management, there is a wide range of po...
BACKGROUND: The aim of this multicenter trial was to prospectively evaluate neo-adjuvant chemotherap...
HYPOTHESIS: The effectiveness of extrapleural pneumonectomy (EPP) to extend quality-adjusted surviva...
INTRODUCTION: Malignant pleural mesothelioma is an ideal model for testing new locoregional multimod...